BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
Go back to BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 65.08 +0.35 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.73 | 52 Week High | $108.96 | |||
| Open | $65.34 | 52 Week Low | $62.12 | |||
| Day High | $66.21 | P/E | N/A | |||
| Day Low | $64.97 | EPS | $-1.27 | |||
| Volume | 1,380,616 | |||||
